Madeed
Riyadh-based startup founded in 2025 that sells a membership combining biomarker blood testing, physician-led review and personalised health protocols, backed by $925,000 of pre-seed funding.
Industry: Preventive health and longevity | Location: Riyadh, Saudi Arabia | Founded: 2025 | Total Funding: USD 400K
About Madeed
Madeed is a Riyadh-based preventive health and longevity startup. It runs a membership model that combines advanced biomarker and blood testing, physician-led interpretation and personalised health protocols covering metabolic health, hormonal balance, cardiovascular risk and inflammation markers. Its laboratory testing screens for early risk signals associated with hundreds of conditions, with the aim of surfacing disease risk before symptoms appear and giving members an actionable plan. One distinctive product is a daily supplement customised to each member's lab results rather than to general wellness guidelines.
The company was founded in 2025 by Dr. Adam Bataineh, a physician who serves as founder and CEO. He was previously chief medical officer of Span Health, a US health coaching platform acquired by Eight Sleep in 2022, after which he joined Eight Sleep's product team. Madeed's website also describes AI-driven digital health solutions for providers, insurers and government institutions in Saudi Arabia, and states that it works in partnership with Albert Health as part of its delivery model.
Madeed has raised USD 925,000 in total across two pre-seed closes. The first, announced in January 2026, was USD 400,000 and was led by Vision Ventures, with Saudi angel investors Mashhoor Aldubayan, Mazen Aldarrab and Abdulla Nadeem Elyas taking part. Vision Ventures invests across the Kingdom and the wider MENA region; its second fund, Saqr Fund II, targets USD 90 million, invests from pre-seed to pre-Series B, and received a USD 15 million commitment from Saudi Venture Capital Company (SVC). The January money was earmarked for finalising product development, expanding clinical and laboratory partnerships and launching the first cohort of members.
In May 2026 Madeed announced additional pre-seed funding from SEEDRA Ventures, Unity Investment Partners and Seen Growth, raising the total to USD 925,000, which implies about USD 525,000 in the second close.
Before that announcement, Madeed completed operational testing of its platform and onboarded around 150 users in a pilot. Bataineh said that phase was meant to ensure efficiency, smooth operation and integration of services ahead of a broader rollout. The new capital is going toward product development, expanding clinical and laboratory partnerships and extending the platform's availability across Saudi Arabia. Expansion beyond the Kingdom has not been ruled out, but the stated priority is proving the model in the home market.
The company's focus aligns with the Kingdom's Health Sector Transformation Program and Vision 2030 priorities on prevention and chronic disease, including diabetes, obesity and cardiovascular conditions. No valuation has been disclosed.
Leadership
- Dr. Adam Bataineh, Founder